Celexa and Daytrana drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Celexa (citalopram hydrobromide) and Daytrana (methylphenidate). Common drug interactions include aneurysm ruptured among females and application site erythema among males.

The phase IV clinical study analyzes what interactions people have when they take Celexa and Daytrana. It is created by eHealthMe based on reports of 52 people who take the same drugs from the FDA, and is updated regularly.

What is Celexa?

Celexa has active ingredients of citalopram hydrobromide. It is often used in depression. eHealthMe is studying from 56,390 Celexa users. Check the latest studies of Celexa.

What is Daytrana?

Daytrana has active ingredients of methylphenidate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 16,561 Daytrana users. Check the latest studies of Daytrana.

On Jul, 14, 2026

52 people who take Celexa and Daytrana together, and have interactions are studied.

What are the common drug interactions of Celexa and Daytrana, by gender? *:

female:

Aneurysm ruptured (expansion of the aneurysm reaches a point where the wall becomes too thin, the aneurysm will rupture)
Drug administration error
Overdose
Retinal aneurysm (an abnormal dilatation of an retinal artery)
Anaemia (lack of blood)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Abdominal discomfort
Cerebral haemorrhage (bleeding within the brain)
Decreased appetite
Disturbance in social behaviour

male:

Application site erythema (redness of the skin at application site)
Application site rash
Abnormal behaviour
Accidental exposure
Appendicitis (inflammation of the appendix)
Application site dryness
Application site irritation
Application site pain
Application site pruritus (application site severe itching of the skin)
Application site swelling

What are the common drug interactions of Celexa and Daytrana, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Drug effect delayed
Appendicitis (inflammation of the appendix)
Application site swelling
Drug administration error
Drug ineffective
Application site erythema (redness of the skin at application site)

10-19:

Application site erythema (redness of the skin at application site)
Drug ineffective
Drug administration error
Impulse-control disorder
Overdose
Psychomotor hyperactivity (feelings of extreme restlessness)
Anaemia (lack of blood)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Abdominal discomfort
Abdominal pain upper

20-29:

Disturbance in attention
Irritability
Drug administration error

30-39:

n/a

40-49:

Aneurysm ruptured (expansion of the aneurysm reaches a point where the wall becomes too thin, the aneurysm will rupture)
Retinal aneurysm (an abnormal dilatation of an retinal artery)
Cerebral haemorrhage (bleeding within the brain)
Intracranial aneurysm (bulging, weak area in the wall of a cranial artery)
Medical device complication
Post procedural complication

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Stress And Anxiety: 13 people, 25.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 5.77%

* Approximation only. Some reports may have incomplete information.

Do you take Celexa and Daytrana?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously